Total Payments
$3,452
2023 Payments
$97.24
Companies
39
Transactions
226
Medicare Patients
5,676
Medicare Billing
$2.2M
Payment Breakdown by Category
Food & Beverage$3,318 (96.1%)
Education$104.97 (3.0%)
Gifts$29.42 (0.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,318 | 221 | 96.1% |
| Education | $104.97 | 4 | 3.0% |
| Gift | $29.42 | 1 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $541.73 | 46 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $392.09 | 25 | $0 (2022) |
| Merck Sharp & Dohme LLC | $248.88 | 17 | $0 (2022) |
| Genentech USA, Inc. | $208.12 | 25 | $0 (2019) |
| Pharmacyclics LLC, An AbbVie Company | $203.89 | 9 | $0 (2023) |
| Eisai Inc. | $173.37 | 6 | $0 (2020) |
| Janssen Biotech, Inc. | $151.62 | 9 | $0 (2019) |
| AbbVie Inc. | $134.68 | 9 | $0 (2021) |
| PFIZER INC. | $131.07 | 10 | $0 (2019) |
| Amgen Inc. | $127.59 | 6 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $97.24 | 4 | Pharmacyclics LLC, An AbbVie Company ($42.09) |
| 2022 | $45.33 | 3 | G1 Therapeutics, Inc. ($17.83) |
| 2021 | $175.82 | 11 | AbbVie Inc. ($74.15) |
| 2020 | $207.36 | 10 | Pharmacyclics LLC, An AbbVie Company ($59.99) |
| 2019 | $1,342 | 95 | E.R. Squibb & Sons, L.L.C. ($212.62) |
| 2018 | $935.85 | 60 | E.R. Squibb & Sons, L.L.C. ($163.32) |
| 2017 | $648.82 | 43 | Novartis Pharmaceuticals Corporation ($183.06) |
All Payment Transactions
226 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/15/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 06/02/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: ONCOLOGY | ||||||
| 04/26/2023 | US Oncology Corporate, Inc. | — | Gift | Cash or cash equivalent | $29.42 | General |
| 03/04/2023 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $25.73 | General |
| Category: ONCOLOGY | ||||||
| 05/25/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), FEMARA | Food and Beverage | In-kind items and services | $12.70 | General |
| Category: ONCOLOGY | ||||||
| 05/11/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $14.80 | General |
| Category: ONCOLOGY | ||||||
| 03/21/2022 | G1 Therapeutics, Inc. | COSELA (Drug) | Food and Beverage | Cash or cash equivalent | $17.83 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2021 | AbbVie Inc. | CREON (Drug) | Food and Beverage | In-kind items and services | $19.92 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/07/2021 | AbbVie Inc. | CREON (Drug) | Food and Beverage | In-kind items and services | $11.43 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/08/2021 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $21.06 | General |
| Category: ONCOLOGY | ||||||
| 09/16/2021 | AbbVie Inc. | CREON (Drug) | Food and Beverage | In-kind items and services | $13.67 | General |
| Category: ENDOCRINOLOGY | ||||||
| 08/20/2021 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $13.31 | General |
| Category: ONCOLOGY | ||||||
| 06/28/2021 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $19.07 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 05/26/2021 | AbbVie Inc. | CREON (Drug) | Food and Beverage | In-kind items and services | $11.23 | General |
| Category: ENDOCRINOLOGY | ||||||
| 05/10/2021 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $17.34 | General |
| Category: ONCOLOGY | ||||||
| 03/31/2021 | TerSera Therapeutics LLC | Xermelo (Drug) | Food and Beverage | In-kind items and services | $18.97 | General |
| Category: Oncology | ||||||
| 01/14/2021 | AbbVie Inc. | CREON (Drug) | Food and Beverage | In-kind items and services | $17.90 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/02/2020 | AbbVie Inc. | CREON (Drug) | Food and Beverage | In-kind items and services | $16.27 | General |
| Category: ENDOCRINOLOGY | ||||||
| 10/29/2020 | AbbVie Inc. | CREON (Drug) | Food and Beverage | In-kind items and services | $15.84 | General |
| Category: ENDOCRINOLOGY | ||||||
| 03/11/2020 | E.R. Squibb & Sons, L.L.C. | INREBIC (Drug) | Food and Beverage | Cash or cash equivalent | $18.99 | General |
| Category: Hematology | ||||||
| 02/19/2020 | E.R. Squibb & Sons, L.L.C. | INREBIC (Drug) | Food and Beverage | Cash or cash equivalent | $11.55 | General |
| Category: Hematology | ||||||
| 02/12/2020 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Food and Beverage | In-kind items and services | $23.10 | General |
| Category: ONCOLOGY | ||||||
| 02/05/2020 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $17.59 | General |
| Category: Oncology | ||||||
| 01/15/2020 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $12.06 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 32 | 1,405 | 61,221 | $657,511 | $396,308 |
| 2022 | 30 | 1,263 | 90,788 | $661,529 | $407,770 |
| 2021 | 33 | 1,419 | 93,487 | $1.0M | $566,952 |
| 2020 | 37 | 1,589 | 141,817 | $1.5M | $868,444 |
Total Patients
5,676
Total Services
387,313
Medicare Billing
$2.2M
Procedure Codes
132
All Medicare Procedures & Services
132 procedure records from CMS Medicare Utilization — Page 2 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 77 | 621 | $530.65 | $306.07 | 57.7% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 40 | 2,696 | $404.40 | $261.91 | 64.8% |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 2023 | 45 | 204 | $316.20 | $201.26 | 63.6% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 36 | 146 | $197.10 | $118.98 | 60.4% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 18 | 104 | $218.40 | $114.88 | 52.6% |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | Office | 2023 | 14 | 75 | $161.25 | $98.41 | 61.0% |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | Office | 2023 | 17 | 864 | $95.04 | $63.88 | 67.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 28 | 10,860 | $273,913 | $177,628 | 64.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 309 | 705 | $104,080 | $59,869 | 57.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 198 | 400 | $82,600 | $50,396 | 61.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 38 | 315 | $48,089 | $31,334 | 65.2% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2022 | 24 | 31,620 | $38,536 | $22,025 | 57.2% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 31 | 349 | $11,853 | $7,890 | 66.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 50 | 50 | $13,021 | $7,527 | 57.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2022 | 22 | 147 | $10,911 | $7,237 | 66.3% |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 2022 | 15 | 29,260 | $15,938 | $6,089 | 38.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 38 | 124 | $9,536 | $5,900 | 61.9% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 29 | 383 | $6,959 | $4,552 | 65.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 60 | 432 | $7,394 | $4,472 | 60.5% |
| 99195 | Drawing of blood for a medical problem | Office | 2022 | 20 | 62 | $7,052 | $4,088 | 58.0% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 13 | 170 | $6,236 | $4,000 | 64.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 43 | 54 | $5,539 | $3,287 | 59.3% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2022 | 22 | 124 | $4,820 | $3,084 | 64.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 11 | 17 | $1,963 | $1,316 | 67.0% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2022 | 12 | 8,400 | $2,588 | $1,091 | 42.2% |
About Dr. Irina Popa, MD
Dr. Irina Popa, MD is a Hematology & Oncology healthcare provider based in Omaha, Nebraska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/25/2005. The National Provider Identifier (NPI) number assigned to this provider is 1649263542.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Irina Popa, MD has received a total of $3,452 in payments from pharmaceutical and medical device companies, with $97.24 received in 2023. These payments were reported across 226 transactions from 39 companies. The most common payment nature is "Food and Beverage" ($3,318).
As a Medicare-enrolled provider, Popa has provided services to 5,676 Medicare beneficiaries, totaling 387,313 services with total Medicare billing of $2.2M. Data is available for 4 years (2020–2023), covering 132 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Omaha, NE
- Active Since 08/25/2005
- Last Updated 06/26/2013
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1649263542
Products in Payments
- OPDIVO (Biological) $395.74
- KEYTRUDA (Biological) $189.48
- Lenvima (Drug) $173.37
- TECENTRIQ (Biological) $163.88
- IMBRUVICA (Drug) $158.61
- ADCETRIS (Biological) $122.21
- FOUNDATIONONE (Device) $120.94
- CREON (Drug) $106.26
- Xermelo (Drug) $105.64
- ALIMTA (Drug) $104.12
- Imbruvica (Drug) $91.02
- Neulasta (Biological) $72.47
- KISQALI (Drug) $69.56
- EMPLICITI (Biological) $68.66
- ELIQUIS (Drug) $68.64
- JADENU (Drug) $65.52
- AFINITOR (Drug) $63.96
- Rubraca (Drug) $57.36
- NINLARO (Drug) $55.55
- SANDOSTATIN (Drug) $50.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Omaha
James Armitage, Md, MD
Hematology & Oncology — Payments: $1.5M
Hematology & Oncology $1.5M
Margaret Block, M.d, M.D
Hematology & Oncology — Payments: $444,214
Hematology & Oncology $444,214
Julie Vose, Md, MD
Hematology & Oncology — Payments: $194,187
Hematology & Oncology $194,187
Peter Silberstein, M.d, M.D
Hematology & Oncology — Payments: $143,878
Hematology & Oncology $143,878
Apar Kishor Ganti, Md, MD
Hematology & Oncology — Payments: $135,871
Hematology & Oncology $135,871
Dr. Krishna Gundabolu, M.d, M.D
Hematology & Oncology — Payments: $75,519
Hematology & Oncology $75,519